龙源期刊网 https://www.doczj.com/doc/539984855.html,
三种氨基水杨酸制剂治疗溃疡性结肠炎的安全性和有效性研究
作者：宋冬梅
来源：《中国医药科学》2014年第04期
[摘要] 目的观察美沙拉嗪、奥沙拉嗪和柳氮磺吡啶治疗溃疡性结肠炎的临床疗效和不良
反应。方法选择120例轻中度溃疡性结肠炎患者，随机分为美沙拉嗪组（n=40）、奥沙拉嗪组（n=39）和柳氮磺吡啶组（n=41），分别接受上述三种药物治疗。美沙拉嗪组和奥沙拉嗪组患者口服药物剂量均为每次1.0g，每日3次；而柳氮磺吡啶组患者服用剂量为每次1.0g，每日4次。治疗12周后观察治疗疗效和不良反应发生情况。结果美沙拉嗪组、奥沙拉嗪组和柳氮磺吡啶组临床有效率分别为30.0%、28.2%和51.2%，总有效率分别为75.0%、76.9%和
92.7%。柳氮磺吡啶组疗效优于美沙拉嗪组、奥沙拉嗪组（P
[关键词] 美沙拉嗪；奥沙拉嗪；柳氮磺吡啶；溃疡性结肠炎
[中图分类号] R574 [文献标识码] B [文章编号] 2095-0616（2014）04-97-03
Study on the safety and efficacy of three amino salicylc acid preparations for treating ulcerative colitis
SONG Dongmei
Department of Gastroenterology， the People's Hospital of Jiawang District in Xuzhou City，Xuzhou 221011， China
[Abstract] Objective To evaluate the therapeutic effects of mesalazine， osalazine and sulfasalazine for patientswith ulcerative colitis. Methods 120 patients with ulcerative colitis were randomly divided into mesalazinegroup（n=40）， osalazine group（n=39） and sulfasalazine group（n=41）. The efficacy and adverse events of the three groups were observed after the treatment of 12 weeks. Results The rate of complete remission and overall effective rate of three
groupswere30.0%， 28.2% and 51.2%； 75.0%， 76.9% and 92.7%， respectively. And the differences between mesalazine/osalazine and sulfasalazine were statistically significant （P
[Key words] Mesalazine； Osalazine； Sulfasalazine； UlcerativeColitis
溃疡性结肠炎（ulcerative colitis，UC）又称慢性非特异性溃疡性结肠炎。它是一种病因不明的局限于结肠黏膜及黏膜下层的慢性非特异性炎症过程，病变多位于乙状结肠和直肠，也可累及至降结肠，甚至整个结肠[1]。临床表现主要包括腹痛、腹泻和黏液脓血便，此外还可合
并胃肠道外的表现如皮肤损害、关节炎等，病情轻重不等，多呈反复发作的慢性病程。目前，